ISSC · Investment summary · as of 4 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $19.47, ISSC requires a 8% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 13%.
The disagreement with the market is about whether the acquisition engine and the organic base keep compounding, not about margin. The margin axis carries large slack in every frame, so it is not where the thesis lives.
The value rests on an exit multiple of 15.9x, a terminal operating margin of 25% and a 9.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: Named cause, not a multiple forecast: the $100m JPM facility (18 July 2025, matures 18 July 2030, priced on a Total Net Leverage grid at SOFR + 1.75-2.75%) is ~79.6% drawn pro forma for Aydin — $79.6m of $100m, ~$20.4m undrawn.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is about whether the acquisition engine and the organic base keep compounding, not about margin. The margin axis carries large slack in every frame, so it is not where the thesis lives. |
| What do we forecast? | Revenue growth of 13% demonstrated; a terminal operating margin of 25%; an exit multiple of 15.9x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +5.3 percentage points. |
| What is it worth? | Twelve-month target $21.00, +8% from the struck price. Scenario-weighted expected return net of costs +7.9%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| FY2026 10-K (~Dec 2026) and FY2027 10-K (~Dec 2027) | (revenue + change in backlog) / revenue, from the 10-K backlog… | Book-to-bill at or above 1.0x for two consecutive fiscal years | Book-to-bill below 1.0x for two consecutive fiscal years |
| FY2026 10-K (~Dec 2026) | The organic vs acquired split the company discloses in the 10-K MD&A | Neither leg of the condition opposite is met at this date | Organic net sales growth below +8% |
| any quarter end through FY2027 | Net debt / TTM EBITDA on the JPM facility's covenant grid | Total Net Leverage at or below 3.0x at any fiscal quarter end | Total Net Leverage above 3.0x at any fiscal quarter end |
| any two consecutive quarters through FY2027 | Reported quarterly gross profit / net sales | Gross margin at or above 45% for two consecutive quarters | Gross margin below 45% for two consecutive quarters |
Named cause, not a multiple forecast: the $100m JPM facility (18 July 2025, matures 18 July 2030, priced on a Total Net Leverage grid at SOFR + 1.75-2.75%) is ~79.6% drawn pro forma for Aydin — $79.6m of $100m, ~$20.4m undrawn. Five of the last five revenue step-ups were bought. If no sixth deal is financeable, the business reverts to its organic base: ~$90-105m of revenue growing at the organic rate, with a book-to-bill of 0.86x in FY2025 and backlog down 13% to $77.4m (of which only $14.9m was organic at 9/30/2024 — the FY2025 revenue surge was substantially the conversion of a PURCHASED backlog). At the 5-year minimum traded multiple of 10.45x on $22.98m of EBIT = $240.2m EV, less pro-forma net debt $72.86m = $167.3m of equity = $9.35/share.
Estimated probability 35%, against the 19% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Exit in full if the price reaches the target while the FY2026 organic split prints below +8%. On approach to the $21.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Named cause, not a multiple forecast: the $100m JPM facility (18 July 2025, matures 18 July 2030, priced on a Total Net Leverage grid at SOFR + 1.75-2.75%) is ~79.6% drawn pro forma for Aydin — $79.6m of $100m, ~$20.4m undrawn. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +5.3 percentage points more growth than the price requires. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $16.91, which forces an immediate review.